FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317660878> ?p ?o ?g. }

• W4317660878 abstract "Abstract Background T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cellular immunotherapy for cancer. Methods We previously developed a human anti-CD19 antibody (ET190L1) and generated novel CD19-specific γ/δ TCR-T cells, ET019003, by fusing the Fab fragment of ET190L1 with γ/δ TCR constant chain plus adding an ET190L1-scFv/CD28 co-stimulatory molecule. ET019003 cells were tested in preclinical studies followed by a phase 1 clinical trial. Results ET019003 cells produced less cytokines but retained comparable antitumor potency than ET190L1-CAR-T cells in vivo and in vitro. In the first-in-human trial, eight patients with relapsed or refractory DLBCL were treated. CRS of grade 1 was observed in three (37.5%) patients; ICANS of grade 3 was noted in one (12.5%) patient. Elevation of serum cytokines after ET019003 infusion was almost modest. With a median follow-up of 34 (range 6–38) months, seven (87.5%) patients attained clinical responses and six (75%) achieved complete responses (CR). OS, PFS and DOR at 3 years were 75.0%, 62.5%, and 71.4%, respectively. Notably, patient 1 with primary CNS lymphoma did not experience CRS or ICANS and got an ongoing CR for over 3 years after infusion, with detectable ET019003 cells in CSF. ET019003 showed striking in vivo expansion and persisted in 50% of patients at 12 months. Three patients received a second infusion, one for consolidation therapy after CR and two for salvage therapy after disease progression, but no response was observed. ET019003 expansion was striking in the first infusion, but poor in the second infusion. Conclusions CD19-specific γ/δ TCR-T cells, ET019003, had a good safety profile and could induce rapid responses and durable CR in patients with relapsed or refractory DLBCL, even primary CNS lymphoma, presenting a novel and potent therapeutic option for these patients. Trial registration : NCT04014894." @default.
• W4317660878 created "2023-01-21" @default.
• W4317660878 creator A5008795534 @default.
• W4317660878 creator A5011673944 @default.
• W4317660878 creator A5012360415 @default.
• W4317660878 creator A5013558797 @default.
• W4317660878 creator A5018833178 @default.
• W4317660878 creator A5019657883 @default.
• W4317660878 creator A5020370573 @default.
• W4317660878 creator A5020471416 @default.
• W4317660878 creator A5021899470 @default.
• W4317660878 creator A5027244110 @default.
• W4317660878 creator A5034750000 @default.
• W4317660878 creator A5037677450 @default.
• W4317660878 creator A5039219495 @default.
• W4317660878 creator A5040647242 @default.
• W4317660878 creator A5042026897 @default.
• W4317660878 creator A5044870711 @default.
• W4317660878 creator A5048815633 @default.
• W4317660878 creator A5063310582 @default.
• W4317660878 creator A5065541267 @default.
• W4317660878 creator A5066607704 @default.
• W4317660878 creator A5082388066 @default.
• W4317660878 date "2023-01-21" @default.
• W4317660878 modified "2023-10-14" @default.
• W4317660878 title "Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma" @default.
• W4317660878 cites W1619537825 @default.
• W4317660878 cites W1989124191 @default.
• W4317660878 cites W2055926684 @default.
• W4317660878 cites W2119147717 @default.
• W4317660878 cites W2133201432 @default.
• W4317660878 cites W2285239684 @default.
• W4317660878 cites W2294816409 @default.
• W4317660878 cites W2305142474 @default.
• W4317660878 cites W2509364267 @default.
• W4317660878 cites W2518731208 @default.
• W4317660878 cites W2598700764 @default.
• W4317660878 cites W2662929969 @default.
• W4317660878 cites W2739972212 @default.
• W4317660878 cites W2744261860 @default.
• W4317660878 cites W2746068181 @default.
• W4317660878 cites W2778172184 @default.
• W4317660878 cites W2793887515 @default.
• W4317660878 cites W2888019042 @default.
• W4317660878 cites W2901117802 @default.
• W4317660878 cites W2903062212 @default.
• W4317660878 cites W2903225254 @default.
• W4317660878 cites W2905654445 @default.
• W4317660878 cites W2936551248 @default.
• W4317660878 cites W2938308258 @default.
• W4317660878 cites W2944689312 @default.
• W4317660878 cites W2971361007 @default.
• W4317660878 cites W2978240167 @default.
• W4317660878 cites W3082855561 @default.
• W4317660878 cites W3087057425 @default.
• W4317660878 cites W3088453061 @default.
• W4317660878 cites W3105850195 @default.
• W4317660878 cites W3128646645 @default.
• W4317660878 cites W3134205746 @default.
• W4317660878 cites W3196726943 @default.
• W4317660878 cites W3202498320 @default.
• W4317660878 cites W3206783250 @default.
• W4317660878 cites W4213165752 @default.
• W4317660878 cites W4220655611 @default.
• W4317660878 cites W4243553605 @default.
• W4317660878 cites W4285490689 @default.
• W4317660878 doi "https://doi.org/10.1186/s13045-023-01402-y" @default.
• W4317660878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36681817" @default.
• W4317660878 hasPublicationYear "2023" @default.
• W4317660878 type Work @default.
• W4317660878 citedByCount "2" @default.
• W4317660878 countsByYear W43176608782023 @default.
• W4317660878 crossrefType "journal-article" @default.
• W4317660878 hasAuthorship W4317660878A5008795534 @default.
• W4317660878 hasAuthorship W4317660878A5011673944 @default.
• W4317660878 hasAuthorship W4317660878A5012360415 @default.
• W4317660878 hasAuthorship W4317660878A5013558797 @default.
• W4317660878 hasAuthorship W4317660878A5018833178 @default.
• W4317660878 hasAuthorship W4317660878A5019657883 @default.
• W4317660878 hasAuthorship W4317660878A5020370573 @default.
• W4317660878 hasAuthorship W4317660878A5020471416 @default.
• W4317660878 hasAuthorship W4317660878A5021899470 @default.
• W4317660878 hasAuthorship W4317660878A5027244110 @default.
• W4317660878 hasAuthorship W4317660878A5034750000 @default.
• W4317660878 hasAuthorship W4317660878A5037677450 @default.
• W4317660878 hasAuthorship W4317660878A5039219495 @default.
• W4317660878 hasAuthorship W4317660878A5040647242 @default.
• W4317660878 hasAuthorship W4317660878A5042026897 @default.
• W4317660878 hasAuthorship W4317660878A5044870711 @default.
• W4317660878 hasAuthorship W4317660878A5048815633 @default.
• W4317660878 hasAuthorship W4317660878A5063310582 @default.
• W4317660878 hasAuthorship W4317660878A5065541267 @default.
• W4317660878 hasAuthorship W4317660878A5066607704 @default.
• W4317660878 hasAuthorship W4317660878A5082388066 @default.
• W4317660878 hasBestOaLocation W43176608781 @default.
• W4317660878 hasConcept C121608353 @default.
• W4317660878 hasConcept C126322002 @default.
• W4317660878 hasConcept C147483822 @default.
• W4317660878 hasConcept C148125776 @default.
• W4317660878 hasConcept C150903083 @default.

• next